About Cytomos
Cytomos is a Healthcare company based in Edinburgh (United Kingdom) founded in 2012. It operates as a point-of-care cell sorter is developed for research and diagnostics. Cytomos has raised $13.55 million across 4 funding rounds from investors including British Business Bank, Scottish Enterprise and Archangels. The company has 15 employees. Cytomos offers products and services including AuraCyt and Celledonia. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Instruments and Cell Biology. Its legal entity is CYTOMOS LIMITED. Its competitors include NanoCellect Biomedical, ThinkCyte, Singulex, Cell Microsystems and Silicon Biosystems and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
Cytomos was founded in 2012 in Edinburgh, United Kingdom, within the biotechnology sector. Operations center on the creation of a point-of-care device designed for cell sorting. This technology targets applications in research laboratories and clinical diagnostics. The companys efforts aim to enable efficient cell analysis at the point of use, supporting advancements in medical and scientific fields across the region.
- Headquarters Edinburgh, United Kingdom
- Employees 15
- SectorsHealthcare
- Email••••••••
- Website cytomos.com
- Social LinkedIn X
- Legal Name Cytomos Limited
- Date of Incorporation 10 Jun, 2011
- Jurisdiction EDINBURGH, SCOTLAND
- Total Equity Funding$13.55M (USD)
in 4 rounds
- Latest Funding Round$6.32M (USD), Series A
Nov 2024
- InvestorsBritish Business Bank
& 3 more
- Employee Count15
Products & Services of Cytomos
Cytomos offers a comprehensive portfolio of products and services, including AuraCyt and Celledonia.
Technology for label-free detection of single-cell attributes in real-time.
Platform supporting multidimensional data generation for cellular analysis.
Funding Insights of Cytomos
Cytomos has successfully raised a total of $13.55M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $6.32 million completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $13.55M
- Total Rounds 4
- Last Round Series A — $6.32M
- First Round $164,770
(Jun 2014)
- Investors Count 4
All 4 funding rounds of Cytomos with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2024 | $6.32M | Series A | – | Archangels | |
| Aug 2023 | $5.1M | Series A | – | Archangels | |
| Jun 2022 | $1.96M | Seed | – | Archangels | |
| Jun 2014 | $164,770 | Seed | – | – | – |
4 investors in total: 4 institutional.
Investors in Cytomos
Cytomos has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include British Business Bank, Scottish Enterprise and Archangels.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment and expertise are provided to early-stage Scottish companies. | – | archangelsonline.com | Edinburgh, Scotland | |
- | – | oldcollegecapital.co.uk | - | |
Private debt fund and fund of funds focused on startups | 2014 | british-business-bank.co.uk | Sheffield, United Kingdom | |
Business development and leadership training programs are offered to companies. | 1991 | scottish-enterprise.com | Glasgow, United Kingdom |
Investor details for Cytomos
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cytomos
4 people are tracked at Cytomos (4 in leadership); the tracked headcount is 15.
| Name | Role | Group |
|---|---|---|
Lindsay Fraser | Chief Scientific Officer | Leadership |
David Rigterink | CEO | Leadership |
Mark Collingbourne | Chief Financial Officer | Leadership |
Abby Miller | Executive Assistant And HR Service Partner | Leadership |
Complete people profiles for Cytomos
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Cytomos
3 dated milestones of Cytomos across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Cytomos is founded.
- Funding First funding round of $165K.
- Funding Latest funding round, Series A, of $6.3M.
Competitors of Cytomos
Cytomos has 9 listed competitors in our database, 9 of them funded. They include NanoCellect Biomedical, ThinkCyte, Singulex, Cell Microsystems and Silicon Biosystems, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| nanocellect.com | 2009 | San Diego, United States | $78.15M | 84 | Develops flow cytometry and cell sorting technology | |
| thinkcyte.com | 2016 | Bunkyo, Japan | $83.18M | – | Cell analysis and sorting technologies are developed with AI integration. | |
| singulex.com | 1997 | Alameda, United States | $140.94M | 236 | Single-molecule counting technology is developed for cardiovascular biomarker detection. | |
| cellmicrosystems.com | 2009 | Durham, United States | $19.1M | – | Developer of a technology to isolate and recover single cells for molecular analysis | |
| siliconbiosystems.com | 1999 | Bologna, Italy | $22.81M | – | Lab-on-a-chip technologies for miniaturized cell-biology testing are developed. | |
| immunicon.com | 1983 | Bryn Athyn, United States | $75.35M | – | Cell and molecular-based diagnostics for cancer management are developed. | |
| fdsonics.com | 2010 | Wilbraham, United States | $34.82M | 7 | Developer of acoustic particle trapping systems for applications in research and public health | |
| cytena.com | 2014 | – | $4.59M | 71 | Single cells are isolated using the cy-Clone device technology. | |
| nodexus.com | 2014 | Berkeley, United States | $31.2M | 27 | Microfluidic systems are developed for detecting metastatic cancer. |
Detailed competitors of Cytomos
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
10 companies that operate in the same segment as Cytomos (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | 1,111 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cytomos
Complete news archive for Cytomos
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cytomos
Cytomos was founded in 2012 and raised its 1st funding round 2 years after it was founded.
Cytomos is headquartered in Edinburgh, United Kingdom. It is registered at Edinburgh, Scotland, United Kingdom.
Cytomos is a funded company, having raised a total of $13.55M across 4 funding rounds to date. The company's 1st funding round was a Seed of $164.77K, raised on Jun 2014.
Cytomos has 15 employees.
Cytomos was founded in 2012 in Edinburgh, United Kingdom, within the biotechnology sector. Operations center on the creation of a point-of-care device designed for cell sorting. This technology targets applications in research laboratories and clinical diagnostics. The companys efforts aim to enable efficient cell analysis at the point of use, supporting advancements in medical and scientific fields across the region.
Cytomos's top competitors include NanoCellect Biomedical, ThinkCyte and Silicon Biosystems.
Cytomos offers AuraCyt and Celledonia.
Cytomos has 4 investors. Key investors include British Business Bank, Scottish Enterprise, Archangels, and Old College Capital.
Cytomos operates through Cytomos Limited.